Large Gap in Performance of New Drugs; Products Including Clenafin, Uptravi Doing Well

By Reiji Anasako

Drug makers’ April-September business results were driven by a weaker yen and growth in sales of global products. The domestic market, however, was sluggish due to the growing use of generics, particularly authorized generics, along with declining sales of long-listed drugs. This underlines the fact that drug makers must now rely on new drugs for revenue. This being the case, can drug makers expect to see steady sales growth of their new drugs? Our analysis of the performance of new drugs, which were launched mainly within the last three years, shows that some products are doing very well, while others are far short of expectations ...